Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
|
31719581 |
2019 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy in myeloproliferative neoplasms (MPN).
|
31286322 |
2019 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor.
|
31289316 |
2019 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib.
|
30571852 |
2019 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN).
|
29907599 |
2018 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The discovery of the activating Janus kinase (JAK)2<sup>V617F</sup> mutation in 2005 in most patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in the gene encoding calreticulin (CALR) in 2013, thus providing additional mechanistic explanations for the universal activation of JAK-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011.
|
29277359 |
2018 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Momelotinib is a potent and selective small-molecule inhibitor of JAK1/2 that is under investigation for the treatment of myeloproliferative neoplasms.
|
29024542 |
2018 |
Myeloproliferative disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation.
|
29515770 |
2018 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
|
29056075 |
2018 |
Myeloproliferative disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib.
|
27677740 |
2017 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib.
|
28028027 |
2017 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL).
|
26443624 |
2015 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Abstract Considering the recent impact of tyrosine kinase inhibitors in the treatment of myeloproliferative disorders carrying a recurrent JAK2 mutation not identified in multiple myeloma (MM), this study aimed to search for mutations in kinase and pseudokinase domains of the JAK1 gene in an attempt to define any critical and recurring change that can be used as a therapeutic target.
|
23885837 |
2014 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN).
|
22875628 |
2013 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
|
20130243 |
2010 |